Global Tech Industries Group Inc (OTCMKTS: GTII) is gearing up for a big week ahead after the Company announced on Sunday evening it has decided to keep the original exercise price of $2.75 for the warrants. Such decision was as a change to the exercise price would require an amendment to the S-1, which could cause the shares common stock issued pursuant to a new exercise price to not be registered at the time of issuance. Shareholders are eligible to exercise their Warrants at the initial exercise price, and receive shares of common stock registered for resale in the S-1 by contacting Liberty Stock Transfer, the company’s transfer agent.
This sets the stage for another big week ahead for GTII which has exploded off its base well under $1 to highs well over $5 per share as the short covering rally continues. Since we first covered GTII in August when the stock was still well below the $1-mark GTII has exploded northbound currently just under $3 per share. GTII is quickly becoming known as the OTC version of Gamestop or AMC with 1 short that is short a massive 100 million shares with little chance to cover and is now in serious trouble as GII continues to rocket up the charts on running 74% on Friday on $45 million in dollar volume.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Global Tech Industries Group Inc (OTCMKTS: GTII) sets the stage and develops the assets to stimulate innovation and growth in emerging businesses on a global basis. The company works across various and diverse industry sectors attempting to find potential partners and assisting them in animating their business plans. Although Global Tech’s staff is limited, it continues to monitor new developments and any emerging technologies that it deems in line with its stated mission as an early-stage company, of acquiring new and innovative technologies in diverse industries. With the acquisition of BAT, Global Tech acquired fifteen (15) intellectual properties pertaining to the construction of the mobile configuration and operation of the glyd-arc medical waste destruction unit, as well as an enhanced configuration and novel method for coal gasification. There is currently no use or activity involving the intellectual properties of the Company, and accordingly, there is no recorded value assigned to these assets.GTII is in the process of animating a digital platform, formed together with Alt5 Sigma, for the purpose of acquiring fine art and other collectibles that will be tokenized and eventually issued to its shareholders as Tokenized value dividends. This undertaking signifies a new and revolutionary method for offering value to GTII shareholders and as a way of participating in the shared ownership of fine art and collectibles using Non-fungible tokens.
Global Tech Industries Group, Inc. is a Nevada corporation which has been operating under several different names since 1980. estern Exploration, Inc., a Nevada corporation, was formed on July 24, 1980. In 1990, Western Exploration, Inc. changed its name to Nugget Exploration, Inc. On November 10, 1999, a wholly owned subsidiary of Nugget Exploration, Inc., Nugget Holdings Corporation, merged with and into GoHealthMD, Inc., a Delaware corporation. Shortly thereafter, Nugget Exploration, Inc. changed its name to GoHealthMD, Inc., a Nevada corporation. n August 18, 2004, GoHealthMD, Inc., the Nevada Corporation, changed its name to Tree Top Industries, Inc. On July 7, 2017, Tree Top Industries, Inc. changed its name to Global Tech Industries Group, Inc. TTII Strategic Acquisitions & Equity Group, Inc., a Delaware corporation, G T International Group, Inc. a Wyoming corporation and Global Tech Health, Inc. a Nevada corporation, all were formed by GTII in the anticipation of technologies, products, or services being acquired. Not all subsidiaries have current operations.
Beginning in April of 2021, the Company has been working towards tokenizing its fine art collection. If our prospectus is approved, the Company would mint 1,000,000,000 tokens of the GFT Token, with 26,000,000 of them being registered for distribution. Once minted, each shareholder, as of the to be determined record date, would be entitled to receive one GFT Token for every 10 shares of GTII Common Stock beneficially held in their name.
To Find out the inside Scoop on GTII Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Earlier this month GTII said its board of directors approved management’s request to lower the original strike price of the Warrants, which were distributed last year to a new strike price of $2.00. While the original strike price of $2.75 appears to be within reach, the Company is desirous of rewarding its loyal shareholders with an opportunity to participate at a lower price. The process to change the strike price, and to register the underlying stock with such new strike price, will be underway shortly.
On October 2 GTII announced management, after further market study and input from its legal team, has decided that it is in the best interest of the shareholders of the Company to keep the original exercise price of the warrants it distributed last year. Such decision was made because the common stock underlying the Warrants were registered with the Securities and Exchange Commission in a registration statement on Form S-1 that was declared effective on August 26, 2021 with an exercise price of $2.75. A change to that exercise price would require an amendment to the S-1, which could cause the shares common stock issued pursuant to a new exercise price to not be registered at the time of issuance. As the warrant distribution was originally instituted to reward loyal shareholders and allow them to trade the registered shares of common stock underlying the Warrants, the change to the exercise price has been abandoned, and the Warrants will remain priced as registered for resale by the named selling shareholders in the S-1. Therefore, such shareholders are eligible to exercise their Warrants at the initial exercise price, and receive shares of common stock registered for resale in the S-1 by contacting Liberty Stock Transfer, Inc. (“Liberty”), the company’s transfer agent.
GTII rocketed up more than 74% on Friday as the stock is quickly becoming among the most talked about stocks in small caps. Currently there is a single short on GTII that is 100 million shares short and is in serious trouble. GTII is gearing up for a big week ahead after the Company announced on Sunday evening it has decided to keep the original exercise price of $2.75 for the warrants. Such decision was as a change to the exercise price would require an amendment to the S-1, which could cause the shares common stock issued pursuant to a new exercise price to not be registered at the time of issuance. Shareholders are eligible to exercise their Warrants at the initial exercise price, and receive shares of common stock registered for resale in the S-1 by contacting Liberty Stock Transfer, the company’s transfer agent.This sets the stage for another big week ahead for GTII which has exploded off its base well under $1 to highs well over $5 per share as the short covering rally continues. Since we first covered GTII in August when the stock was still well below the $1-mark GTII has exploded northbound to well over $5 per share. We will be updating on GTII when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in GTII either long or short and we have not been compensated for this article
MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 – $2.5299, with more than 2.98M shares exchanging hands.
So why did MTC surge today ?
The failure of Silicon Valley Bank led to a sell-off in equities and a shift to safe-haven assets, such as US Treasuries and gold. Markets have calmed down somewhat, and the worst of the equity sell-off seems to be over. However, the market anticipates that the markets will be somewhat uneasy until a better understanding of inflation is reached and what the Federal Reserve will do next week.
To Find out the inside Scoop on MTC, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Despite most investors currently avoiding the banking sector, Wall Street sees potential opportunities, particularly in regional banks. The chaos in the market has created opportunities in the industry and several banking stocks are being punished just for being a banking stock. The collapse of Silicon Valley Bank was due to its specialisation in venture-capital financing, which made it vulnerable to the higher interest rate regime of the past 12 months.
For more on MTC Subscribe Right Now!
Therfore, today’s gains in MTC seems to be more a sympathy bounce considering the overall banking sector. Earlier in March, MMTEC, Inc. (Nasdaq: MTC) declared that it will relocate its operations from Beijing to the Hong Kong Special Administrative Region, effective March 6, 2023. The Company’s subsidiary, MM Future Technology Limited, which is a Hong Kong incorporated limited company, will assume all operations previously conducted by its subsidiary, Gujia (Beijing) Technology Co., Ltd. However, Gujia will continue to carry out specific technical research and development functions. Further, the Company, through its subsidiary HC Securities (HK) Limited, and other entities, will continue to invest its human resources in asset management and securities underwriting, and other related businesses, aiming to attract global funds to invest in the Chinese market and support China’s economic growth. The Company’s new operations headquarters is located at Room 2302, 23rd Floor, FWD Financial Center, 308 Des Voeux Road Central, Sheung Wan, Hong Kong.
We will be updating on MTC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MTC.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have no position in MTC and have not been compensated for this article.
Cazoo Group Ltd (NASDAQ: CZOO) last traded at $2.62, a gain of +0.6400 (+32.32%). More than 5M shares exchanged hands compared to an average daily volume of 228K shares. Considering that the 52 week high of CZOO is more than 65$, there seems to be a lot of room to the upside.
To Find out the inside Scoop on CZOO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Why did CZOO surge last week? Welcome to the Carvana of the UK!
Cazoo, a publicly traded company (NYSE: CZOO), was founded in 2018 by serial entrepreneur Alex Chesterman OBE. The company’s mission is to revolutionize the UK’s car buying and selling experience by offering consumers better selection, value, transparency, convenience, and peace of mind. Cazoo’s goal is to make the car buying or selling process as simple as purchasing any other product online. The company enables customers to buy, sell, or finance a car entirely online, with delivery or collection available in as little as 72 hours.
Recently, Cazoo Group Ltd, the UK’s leading online car retailer, updated its business performance and progress with the restructuring announced in January. The CEO, Alex Chesterman, expressed satisfaction with the progress made so far in 2023, despite the challenging economic environment. The company has taken swift and decisive management action to restructure the group, improve unit economics, and reduce fixed costs. The rightsizing of headcount and operational footprint is well underway, and the company expects to complete the restructuring before the end of Q1 2023. The company has seen significant improvement in its GPU, with retail GPU tracking at approximately £900, up from £600 in Q4 2022. Cazoo has sold over 100,000 cars entirely online in the UK in the three years since its launch. The company remains fully focused on driving higher profitability and has appointed Jonathan Dunkley as Chief Operating Officer. Cazoo’s cash reserves remain strong, and the company expects to achieve profitability without external funding until H2 2024. The company expects to end 2023 with over £100m of cash and cash equivalents on its balance sheet and sell 40,000-50,000 UK retail units in the current year.
For more on CZOO, Subscribe Right Now!
The online car market in the UK has been growing rapidly in recent years, driven by increasing consumer demand for convenience and transparency in the car buying process. Online car retailers such as Cazoo, Carzam, and Cinch have emerged as major players in the market, offering a wide selection of used cars for sale online with home delivery or pickup options. These companies use advanced technology to provide customers with a seamless buying experience, including virtual vehicle inspections, transparent pricing, and easy financing options. The COVID-19 pandemic has further accelerated the shift towards online car buying as consumers seek to avoid in-person interactions and dealerships adapt to new ways of doing business.
So if CZOO learns from Carvana’s mistake, there is little to no doubt that CZOO could be the talk of the town in days to come. We will be updating on CZOO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CZOO.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in CZOO, either long or short, and we have not been compensated for this article
Shares of Ocean Biomedical (NASDAQ:OCEA) surged more than 100% on Thursday, following a talk by the company’s scientific co-founder, Dr. Jack A. Elias, at Brown University’s Legorreta Cancer Center. The preclinical-stage biotech, which went public on the NASDAQ on February 15, focuses on developing novel treatments for deadly diseases, including malaria, multiple cancers, and pulmonary fibrosis.
During the talk, Dr. Elias presented exciting details about potential therapies to suppress tumors in various cancers, focusing on the company’s work in understanding the role of the protein Chitinase 3-like-1 (CHI3LI) in the progression of lung cancer. He also discussed his discoveries on how certain monospecific and bispecific antibodies can be used as therapies to treat non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The company aims to expedite these findings into phase 1 trials.
To Find out the inside Scoop on OCEA, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
The excitement over this preliminary news stems from the large target groups for both diseases. According to Cancer.net statistics, NSCLC is the leading cause of cancer death and the second-most diagnosed cancer in the US, affecting around 236,740 people. GBM is the most common primary brain tumor in adults, with an average survival period of just 15 months and no cure.
The recent surge in Ocean Biomedical’s shares also comes on the heels of an announcement on February 28 that co-founder Dr. Jonathan Kurtis had been awarded a patent for the discovery of the third parasite target PfCDPK-5. This target has the potential to be used to halt the malaria parasite in various stages of its cycle, opening up new possibilities for treating this deadly disease.
Ocean Biomedical’s focus on developing novel treatments for deadly diseases and its recent exciting findings have generated significant investor interest. However, it is important to note that investing in preclinical-stage biotech companies carries a high level of risk. There is no guarantee that these discoveries will translate into effective treatments or that the company will receive regulatory approval.
For more on OCEA Subscribe Right Now!
Nevertheless, the positive developments from Ocean Biomedical are a significant milestone and hold great promise for patients suffering from deadly diseases such as cancer and malaria. If the company’s discoveries prove successful in further clinical trials, they could potentially generate significant revenue and transform the standard of care for these diseases. We will be updating on OCEA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OCEA.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in OCEA, either long or short, and we have not been compensated for this article